The well-established antagonist activity of clemastine against H1R and the inhibitory effects of M1R and M3R signaling on oligodendrocyte differentiation [72,73] prompted us to determine the expression profiles of these three receptor genes (HRH1, CHRM1, and CHRM3) in gliomas. This evidence concerns the gene CHRM3 and central nervous system cancer.